

# COVID-19 Update

Adam Crum, DHSS, Commissioner

Dr. Anne Zink, DHSS, Chief Medical Officer

Heidi Hedberg, DHSS, Division of Public Health Director

Dr. Joe McLaughlin, DHSS, Section of Epidemiology Chief and State Epidemiologist


October 21, 2020




# COVID-19 Dashboard

10/21/20 Reporting Data from 10/20/20

- **204 additional Alaskans who have tested positive for COVID-19** (11,605 total)
- **1 additional Alaskan death** (68 total)
- **41 Alaskans currently hospitalized** (375 total)



# Alaska COVID-19 Cases - State Comparison






# Public Health Capacity

Testing	Broad testing	testing >2% of the population / month	testing < 2% of the population / month	testing <1 % of the population / month
	Testing enviroment	little to no limiations in the testing capacity, most areas are able to get testing supplies	reagent shortages impacting communities ability to test but alternitives usually avalabile.	regular shortages with no few or no alternitives and mulitple communities without regular testing access
	Lab turn around	< 48 hrs to run test	48 - 96 hrs to run test	> 96 hrs to run test
Contact tracing?	Average close contacts / per case	mostly small groups	mix of group sizes	many large groups and hard to trace contact many people
	Percent of new cases contacted in < 24 hrs	> 90%	50 - 90%	< 50%

# COVID-19 Contact Tracing




# Epidemiology

Key Question	Indicator	Level 1 Minimal	Level 2 Moderate	Level 3 High
<b>What is the level of disease burden and how is it changing?</b>	Level of community transmission (active cases over 14 days)	Minimal < 5 cases / 100,000	Moderate transmission with some undetected cases 5-10 cases / 100,000	Widespread community transmission with many undetected cases and frequent discrete outbreaks >10 cases / 100,000
	Rt	<1	1.0 - 1.2 *	> 1.2 *
	Nature of outbreaks	Discrete small, isolated cases and easily contained.	Multiple discrete outbreaks, one or more outbreaks in at risk populations	Multiple outbreaks that involve multiple communities that are hard to contain or multiple outbreaks with high risk populations
<b>Are there early signs of a resurgence in cases?</b>	Increasing percent positive rate	Test positive rate <2%	Test % positive rate 2-5%	Test % positive rate >5%
	New case rate over 7 days including non-residents cases	<5 cases/ 100,000 per day	5-10 cases / 100,000	>10 cases / 100,000
	Syndromic data (CLI)	Low to average	Above average	Above average and rising

# COVID-19 Trends and Outlook –

## Epidemic Curve by Onset Date, Statewide


We are accelerating, but the hospital system has remained stable




# Alaska Alert Level: High

Average daily case rate: 25.76 per 100,000 population

Last week, Alaska had 187 new cases per 100,000 population, compared to a national average of 117 per 100,000



Average daily case rate (14 day window) per 100,000 population, Statewide





# Regional Alert Levels

14-Day Avg. Case Rates per 100,000 people

ALERT LEVEL	Average daily incidence over the past 14 days	Interpretation
HIGH	>10 cases per 100,000 population	Widespread community transmission with many undetected cases and frequent discrete outbreaks
INTERMEDIATE	5-10 cases per 100,000 population	Moderate community transmission with some undetected cases and infrequent discrete outbreaks
LOW	<5 cases per 100,000 population	Minimal community transmission


Region	14-Day Avg. Case Rate/ 100,000	Alert Level	Testing % Positivity
Northwest	35.15	HIGH	
YK Delta	36.11	HIGH	7.90%
Fairbanks	30.99	HIGH	7.10%
Anchorage	34.75	HIGH	5.60%
Other Interior	20.11	HIGH	
Juneau	15.19	HIGH	3.70%
Kenai Peninsula	16.03	HIGH	5.35%
Mat-Su	16.03	HIGH	7.33%
Southwest	8.65	INTERMEDIATE	
Other Southeast-Southern	4.3	LOW	
Other Southeast-Northern	4.89	LOW	

# Testing - Statewide % of Daily Tests with Positive Results

7-day rolling average

- 547,140 total tests
- **4.61%** of tests were positive over past 7 days (10/20/2020)

Statewide Percentage of Daily Tests with Positive Results  
(Seven day rolling average)



# Hospital Capacity


Key Question	Indicator	Level 1 Minimal	Level 2 Moderate	Level 3 High
<b>Overall bed capacity</b>	Total hospital bed capacity	< 50% capacity	50- 75% capacity	> 75% capacity
	Total ICU bed capacity	< 50 % capacity	50-75% capacity	> 75% capacity
<b>Hospital bed projections</b>	Projection hospital bed or ICU capacity availability	> 6 weeks before beyond capacity	3- 6 weeks until ICU or acute beds are beyond capacity	<3 weeks until ICU or acute beds are beyond capacity
<b>Anchorage bed capacity</b>	Anchorage hospital bed capacity	< 80% capacity	80% - 90% capacity	> 90% capacity
	Anchorage ICU bed capacity	< 80% capacity	80% - 90% capacity	> 90 % capacity

# Hospital Capacity


## Statewide



## Anchorage




# COVID-19 Hospitalization Rate by Age Group






# COVID-19 Death Rate by Age Group



# Excess Deaths, *JAMA*

Published October 12, 2020

From late January to early October 2020, the U.S. has had 299,000 excess deaths (more deaths than the typical number during the same period in previous years). At least 2 out of 3 of these excess deaths were from COVID-19. Source: CDC



# Excess Deaths by Condition - Alaska

## Jan – Aug 2020

Excess deaths from suicides and homicides slightly down, heart disease, cancer, diabetes and chronic liver disease are slightly up

	ALL CAUSES	INFLUENZA AND PNEUMONIA	DISEASES OF THE HEART	MALIGNANT NEOPLASMS	CHRONIC LOWER RESPIRATORY DISEASES	INTENTIONAL SELF-HARM (SUICIDE)	ASSAULT (HOMICIDE)	MOTOR VEHICLE ACCIDENTS	ALL UNINTENTIONAL INJURIES (including Motor Vehicle Accidents)	CEREBROVAS CULAR DISEASES	DIABETES	NEPHRITIS, NEPHROTIC SYNDROME AND NEPHROSIS	CHRONIC LIVER DISEASE AND CIRRHOSIS
Counts	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug	Jan-Aug
2017	2,839	42	532	592	128	124	50	65	289	114	83	32	74
2018	2,928	54	517	638	162	132	34	59	265	138	83	29	77
2019	3,020	36	531	672	139	137	47	61	293	139	74	35	67
Avg. 2017-19	2,929	44	527	634	143	131	44	62	282	130	80	32	73
2020 <sup>1</sup>	3,109	40	560	648	140	129	28	54	282	123	108	34	91
Excess Deaths (2020-Avg)	180	-4	33	14	-3	-2	-16	-8	0	-7	28	2	18

# This spring and summer, Alaskans together may have prevented over 400 additional deaths from COVID-19

Evergreen Economics Report,  
October 9, 2020

**Table 3: Counterfactual COVID Metrics for Alaska Under the Assumption Alaska Experienced the Average Rates of Infection, Hospitalization, and Death as the Six Peer States**

COVID-19 Metric	Alaska Actual COVID-19 Cases (as of 10/08/20)	Counterfactual COVID Cases	Difference*
Positive Cases	9,005	16,101	7,096
Hospitalizations	320	964	644
Deaths	60	219	159

\* Computed as counterfactual minus actual; represents how many more positive cases, hospitalizations, and deaths Alaska would have experienced if its COVID rates followed the average of its designated peers.

**Table 4: Counterfactual COVID Metrics for Alaska Under the Assumption Alaska Experienced the Average Rates of Infection, Hospitalization, and Death as the U.S.**

COVID-19 Metric	Alaska Actual COVID-19 Cases (as of 10/08/20)	Counterfactual COVID Cases	Difference*
Positive Cases	9,005	16,715	7,710
Hospitalizations	320	1,308	988
Deaths	60	470	410

\* Computed as counterfactual minus actual; represents how many more positive cases, hospitalizations, and deaths Alaska would have experienced if its COVID rates followed the average of the U.S.

# Seasonal Influenza and COVID-19

- Last year, Alaska's influenza case fatality rate was **0.14%**; **U.S. 0.05%**
- Current Alaska COVID case fatality rate is **0.63%**; **U.S. 3%**
- Since February 1, 2020, **30 times more Americans died with COVID-19 than flu**
- COVID-19 is both more widespread in the U.S. and more deadly than the flu
- People with COVID-19 are **15 times as likely** to arrive at a healthcare setting and be found dead on arrival compared to flu, and more than **7x as likely** to die at home.
- **Children between age 1 and age 14** were the only age group more likely to die of flu than COVID-19.

Age	COVID deaths	Flu deaths	COVID vs. Flu
<1	22	16	1.4
1-4	15	42	0.4
5-14	37	53	0.7
15-24	374	55	6.8
25-34	1588	151	10.5
35-44	4119	249	16.5
45-54	10837	580	18.7
55-64	25971	1244	20.9
65-74	43927	1458	30.1
75-84	53796	1484	36.3
85+	62357	1390	44.9
Total	203043	6722	30.2



# 117,044 Alaskans Vaccinated Against Flu



August 1 - October 20									
	6 months - 10 years	11-20 years	21-30 years	31-40 years	41-50 years	51-60 years	61-64 years	65+ years	Total Administered
18-19 Flu Season	12103	6962	7058	8867	8046	12184	6386	22443	84049
19-20 Flu Season	15177	8552	8318	10683	9256	12925	6811	23314	95036
20-21 Flu Season	15915	11562	8784	12421	11556	15820	8772	32214	117044

# COVID-19 Emergency Response Phases

Where are we now?

- **Phase I** *March through May 2020* – Initial response – learning
- **Phase II** *June through September 2020* – Sustained response with low numbers
- **Phase III** *October 2020 to present* – Maximizing Healthcare Capacity and Response

# DHSS Phase III Response Plan

## Contact Tracers – Within 48 hours

- Maximize contact tracer calls by reducing questions, increase education
- Collaborative contact tracing staffing
- Implement text communication

## COVID Testing – Access in Every Community

- Buildup testing supplies stockpile
- Maintain increased State Lab capacity
- Timely results

## Hospital Capacity – Keep Alaskans in Alaska

- Maximize patient movement
- Diversify staffing resources – incorporate allied health professionals
- Maintain Alternate Care Sites


## Data – Timely, transparent and relevant data

- Data integration
- Track outbreak
- Dashboard

## Community Response – Support


- Strike Teams
- Technical assistance to communities
- Technical assistance to clinics
- Mental health response

# COVID-19 Vaccine Planning and Distribution




- Safety of COVID-19 vaccine is top priority
- Partnership with DHSS + Alaska Native Tribal Health Consortium
- Clinical Trials – multiple vaccines are being developed and tested
- COVID-19 vaccine will be approved by the Food & Drug Administration (FDA)
- Following guidance from the CDC, we are planning for a possible limited vaccine supply by end of the year, and more widespread vaccine availability Jan-March 2020

# What We Can Do – Layer on Protections





# What We Can Do – Flatten the Curve





# Stay Safe, Be Well, Be Kind



[COVID19.ALASKA.GOV](https://COVID19.ALASKA.GOV)